Neurotez

Deal To Watch
BETA

Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.

Analytics

Raised to Date: $225,594

Aggregate Commitments $
Platform

Netcapital

Start Date

08/19/2019

Close Date

05/04/2021

Min. Goal

$10,000

Max. Goal

$500,000

Min. Investment

$2

Security Type

Equity - Common

Funding Type

RegCF

Series

Series A

Pre-Money Valuation

$21,959,058

Weekly Commitments $
Status

Active

Reporting Date

02/28/2021

Days Remaining

63

% of Min. Goal

2,256%

% of Max. Goal

45%

Likelihood of Max
Avg. Daily Raise

$404

Momentum
Location
Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2C

Margin

High

Capital Intensity

High

Business Type

Growth

Neurotez, with a post-money valuation of $22.5 million, is raising funds on NetCapital. The company is developing a hormone replacement therapy named Memtin to treat Leptin deficiency in Alzheimer’s patients. The drug will help slow down the cognitive decline in Alzheimer’s patients and other forms of dementia. Neurotez is led by Nikolaos Tezapsidis as the President and CEO, and Wes Ashford as the Chief Medical Officer. The company has already raised $4.5 million in funding from the National Institute of Health, IRS, and New Jersey Commission of Science and Technology. The current crowdfunding round has a minimum goal of $10,000 and a maximum goal of $500,000, and the proceeds will be used for the various studies, clinical trials, manufacturing, personnel costs, and debt repayment. Neurotez has already received many rewards and recognitions and is backed by an excellent team of experts.

Summary Profit and Loss Statement
Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-317,211

$-134,154

Summary Balance Sheet
Most Recent Year Prior Year

Cash

$7,533

$302

Accounts Receivable

$0

$0

Total Assets

$206,070

$221,123

Short-Term Debt

$40,162

$23,336

Long-Term Debt

$26,000

$0

Total Liabilities

$66,162

$43,336

Summary of Crowdfunding Raises
Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
05/04/2021 Netcapital $21,959,058 $225,594 Equity - Common Active RegCF
02/26/2018 Netcapital $0 $95,809 Equity - Common Confirmed Closed RegCF

Ratings

last updated 03/02/2021

Ratings Platform - Beta Trial

Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.

For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.

Analyst Report

Deal To Watch
Ratings Platform - Beta Trial

Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.

For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.
Other Deals

MedVector on StartEngine

The COVID-19 pandemic has grown the telehealth industry exponentially. A recent study of U.S medical specialists found that

Crowd
Phoenix PharmaLabs on Netcapital

In the years before the world’s current COVID-19 crisis, America in particular faced a deadly and persistent threat…

Crowd
C-Reveal Therapeutics on NetCapital

Cancer is the great, mysterious killer of medical science. As of January 2019, there were an

Crowd
Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add Neurotez Inc. on NetCapital
Follow company
Follow Neurotez Inc. on NetCapital